Company intelligence / Profile preview

XoNovo

Ness Ziona, Israel

Ownership: Private
Development stage: Other

Overview

XN-001 has demonstrated encouraging effects in mouse models of Alzheimer's disease by reducing amyloid beta peptide burden, reducing phospho-tau, and relieving cognitive decline[1]. The compound addresses all three hallmarks of AD in experimental triple transgenic mice[1]. Results have been published in multiple peer-reviewed journals[1].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Oklahoma Medical Research Foundation (OMRF) - Exclusive Worldwide Licensing Agreement for intellectual property rights[1]Inoviem Scientific - service-based partnership[3]

Beyond the preview

Go deeper on XoNovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XoNovo.

Explore the full profile